
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): April 17, 2015

XBIOTECH INC.
(Exact name of Registrant as specified in its charter)

British Columbia, Canada
(State of Incorporation)

001-37347
(Commission File Number)

N/A
(I.R.S. Employer Identification No.)

8201 E Riverside Dr. Bldg 4, Ste 100
Austin, Texas
(Address of principal executive offices)

78744
(Zip Code)

(512) 386-2930
(Registrant's telephone number, including area code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 8.01 Other Events.

On April 17, 2015, XBiotech Inc. (the “Company”) closed its previously announced initial public offering. The Company sold 4,000,000 shares of its common stock at an initial public offering price of \$19 per share for a total offering amount of \$76 million, before underwriting discounts and commissions and other company expenses. A copy of the Company’s press release announcing the closing of the offering is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press Release of XBiotech Inc., issued April 17, 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 20, 2015

XBIOTECH INC.

By: /s/ John Simard

John Simard

President

EXHIBIT INDEX

Exhibit
Number

Description

99.1 Press Release, issued April 17, 2015

XBiotech Closes Initial Public Offering

Austin, TX – April 17, 2015 – XBiotech Inc. (NASDAQ: XBIT), a leading developer of next-generation therapeutic antibodies, announced today the closing of its initial public offering of 4,000,000 shares of its common stock at an initial public offering price of \$19.00 per share for a total offering amount of \$76,000,000, before the underwriting discounts and commissions and other company expenses.

WR Hambrecht + Co acted as the sole underwriter for the offering.

This press release shall not constitute an offer to sell nor the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on April 14, 2015. Copies of the final prospectus relating to the offering may be obtained from WR Hambrecht + Co at www.wrhambrecht.com, by calling 1-800-673-6476, or by writing to 909 Montgomery Street, 3rd Floor, San Francisco, CA 94133.

About XBiotech

XBiotech is a leading developer of next-generation therapeutic antibodies. The Company is also innovating with manufacturing technology and clinical strategies to lessen capital requirements and reduce lead times for drug development.

Contact:

Ashley Otero
XBiotech
aotero@xbiotech.com
(512) 386-2930

Tiberend Strategic Advisors:

Joshua Drumm, Ph.D.
jdrumm@tiberend.com (212) 375-2664

Jason Rando (media)
jrando@tiberend.com
(212) 375-2665